Walsky RL - Search Results

1

Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers.

Keirstead ND, Wagoner MP, Bentley P, Blais M, Brown C, Cheatham L, Ciaccio P, Dragan Y, Ferguson D, Fikes J, Galvin M, Gupta A, Hale M, Johnson N, Luo W, McGrath F, Pietras M, Price S, Sathe AG, Sasaki JC, Snow D, Walsky RL, Kern G. Keirstead ND, et al. Among authors: walsky rl. Toxicol Sci. 2014 Feb;137(2):278-91. doi: 10.1093/toxsci/kft247. Epub 2013 Nov 4. Toxicol Sci. 2014. PMID: 24189134

2

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach.

Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. Obach RS, et al. Among authors: walsky rl. Clin Pharmacol Ther. 2005 Dec;78(6):582-92. doi: 10.1016/j.clpt.2005.09.004. Clin Pharmacol Ther. 2005. PMID: 16338274 Review. No abstract available.

3

A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6.

Walsky RL, Obach RS. Walsky RL, et al. Drug Metab Dispos. 2007 Nov;35(11):2053-9. doi: 10.1124/dmd.107.015883. Epub 2007 Aug 6. Drug Metab Dispos. 2007. PMID: 17682072

4

Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.

Walsky RL, Obach RS, Hyland R, Kang P, Zhou S, West M, Geoghegan KF, Helal CJ, Walker GS, Goosen TC, Zientek MA. Walsky RL, et al. Drug Metab Dispos. 2012 Sep;40(9):1686-97. doi: 10.1124/dmd.112.045302. Epub 2012 May 29. Drug Metab Dispos. 2012. PMID: 22645092

5

In vitro cytochrome P450 inhibition and induction.

Walsky RL, Boldt SE. Walsky RL, et al. Curr Drug Metab. 2008 Nov;9(9):928-39. doi: 10.2174/138920008786485128. Curr Drug Metab. 2008. PMID: 18991590 Review.

6

Examination of 209 drugs for inhibition of cytochrome P450 2C8.

Walsky RL, Gaman EA, Obach RS. Walsky RL, et al. J Clin Pharmacol. 2005 Jan;45(1):68-78. doi: 10.1177/0091270004270642. J Clin Pharmacol. 2005. PMID: 15601807

7

Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions.

Obach RS, Walsky RL, Venkatakrishnan K. Obach RS, et al. Among authors: walsky rl. Drug Metab Dispos. 2007 Feb;35(2):246-55. doi: 10.1124/dmd.106.012633. Epub 2006 Nov 8. Drug Metab Dispos. 2007. PMID: 17093004

8

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.

Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. Obach RS, et al. Among authors: walsky rl. J Pharmacol Exp Ther. 2006 Jan;316(1):336-48. doi: 10.1124/jpet.105.093229. Epub 2005 Sep 28. J Pharmacol Exp Ther. 2006. PMID: 16192315

9

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

Walsky RL, Astuccio AV, Obach RS. Walsky RL, et al. J Clin Pharmacol. 2006 Dec;46(12):1426-38. doi: 10.1177/0091270006293753. J Clin Pharmacol. 2006. PMID: 17101742

10

Validated assays for human cytochrome P450 activities.

Walsky RL, Obach RS. Walsky RL, et al. Drug Metab Dispos. 2004 Jun;32(6):647-60. doi: 10.1124/dmd.32.6.647. Drug Metab Dispos. 2004. PMID: 15155557

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters